Please enable JavaScript to continue using this application.

Compare $ACRV vs $RLYB | Chartloom

Compare

$ACRV vs $RLYB

Acrivon Therapeutics Inc · Rallybio Corp

ACRV

Acrivon Therapeutics Inc

RLYB

Rallybio Corp

Compare $ACRV vs $RLYB

Comparing Acrivon Therapeutics Inc and Rallybio Corp

ACRVAcrivon Therapeutics Inc

RLYBRallybio Corp

ACRVAcrivon Therapeutics Inc

Market cap

$82M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-22.4%

52W performance

1.6%

FCF yield

-78.5%

RLYBRallybio Corp

Market cap

$90M

P/E (TTM)

2.17x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-15.1%

YTD performance

200.8%

52W performance

269.6%

FCF yield

29.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACRV

RLYB

Detailed metrics comparison

ACRV

Acrivon Therapeutics Inc

RLYB

Rallybio Corp

Market Cap

ACRV$82M

RLYB$90M

Enterprise Value

ACRV$40M

RLYB$-3M

Price

ACRV$1.91

RLYB$17.02

P/E Ratio

ACRVN/A

RLYB2.17x

P/S Ratio

ACRV0.00x

RLYB139.64x

EV/Sales

ACRV0.00x

RLYB-4.09x

EV/EBITDA

ACRV0.00x

RLYB-0.10x

P/B Ratio

ACRV0.98x

RLYB0.96x

P/FCF Ratio

ACRVN/A

RLYB3.38x

EV/FCF

ACRV-0.63x

RLYB-0.10x

PEG Ratio

ACRVN/A

RLYBN/A

Forward P/E (NTM)

ACRVN/A

RLYBN/A

Forward P/S (NTM)

ACRVN/A

RLYBN/A

Revenue (TTM)

ACRV$0

RLYB$646K

Revenue Growth (YoY)

ACRVN/A

RLYB-15.1%

Forward Rev Growth

ACRV406.9%

RLYB499.1%

Gross Margin (TTM)

ACRV0.0%

RLYB0.0%

Operating Margin (TTM)

ACRV0.0%

RLYB0.0%

EBITDA Margin (TTM)

ACRV0.0%

RLYB-4284.8%

Net Margin (TTM)

ACRV0.0%

RLYB7051.2%

FCF Margin (TTM)

ACRVN/A

RLYB4135.0%

Net Income (TTM)

ACRV$-74M

RLYB$46M

FCF (TTM)

ACRV$-64M

RLYB$27M

EPS (TTM)

ACRV-$1.77

RLYB$7.86

ROE (TTM)

ACRV-7014.0%

RLYB68.6%

ROA (TTM)

ACRV-6161.0%

RLYB64.5%

ROIC (TTM)

ACRV-7014.0%

RLYB68.6%

Cash

ACRV$41M

RLYB$93M

Debt

ACRV$0

RLYB$0

Net Cash/Debt

ACRV$41M

RLYB$93M

Current Ratio (TTM)

ACRV7.99x

RLYB27.26x

Quick Ratio (TTM)

ACRV7.86x

RLYB27.01x

Debt/Equity (TTM)

ACRV0.00x

RLYB0.00x

Debt/Assets (TTM)

ACRV0.0%

RLYB0.0%

Interest Coverage (TTM)

ACRVN/A

RLYBN/A

Net Debt/EBITDA (TTM)

ACRV0.00x

RLYB0.00x

Beta

ACRV1.95

RLYB-0.75

52W Performance

ACRV1.6%

RLYB269.6%

YTD Performance

ACRV-22.4%

RLYB200.8%

% from 52W High

ACRV-46.3%

RLYB-3.2%

% from 52W Low

ACRV50.4%

RLYB363.7%

Asset Turnover (TTM)

ACRV0.00x

RLYB0.01x

FCF Yield (TTM)

ACRV-78.5%

RLYB29.6%

Earnings Yield (TTM)

ACRV-90.8%

RLYB50.5%

Dividend Yield (TTM)

ACRVN/A

RLYBN/A

Rule of 40

ACRV0.0

RLYB4,119.9

EV/GP/RG

ACRVN/A

RLYBN/A

Ticker research

View ACRV research View RLYB research

Metric	ACRV Acrivon Therapeutics Inc	RLYB Rallybio Corp
Market & Valuation
Market Cap	$82M	$90M
Enterprise Value	$40M	$-3M
Price	$1.91	$17.02
P/E Ratio	N/A	2.17x
P/S Ratio	0.00x	139.64x
EV/Sales	0.00x	-4.09x
EV/EBITDA	0.00x	-0.10x
P/B Ratio	0.98x	0.96x
P/FCF Ratio	N/A	3.38x
EV/FCF	-0.63x	-0.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$646K
Revenue Growth (YoY)	N/A	-15.1%
Forward Rev Growth	406.9%	499.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-4284.8%
Net Margin (TTM)	0.0%	7051.2%
FCF Margin (TTM)	N/A	4135.0%
Net Income (TTM)	$-74M	$46M
FCF (TTM)	$-64M	$27M
EPS (TTM)	-$1.77	$7.86
ROE (TTM)	-7014.0%	68.6%
ROA (TTM)	-6161.0%	64.5%
ROIC (TTM)	-7014.0%	68.6%
Financial Health
Cash	$41M	$93M
Debt	$0	$0
Net Cash/Debt	$41M	$93M
Current Ratio (TTM)	7.99x	27.26x
Quick Ratio (TTM)	7.86x	27.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.95	-0.75
52W Performance	1.6%	269.6%
YTD Performance	-22.4%	200.8%
% from 52W High	-46.3%	-3.2%
% from 52W Low	50.4%	363.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-78.5%	29.6%
Earnings Yield (TTM)	-90.8%	50.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	4,119.9
EV/GP/RG	N/A	N/A
Ticker research	View ACRV research	View RLYB research

Valuation

P/E Ratio

RLYB

2.17x

P/S Ratio

ACRV

0.00x

RLYB

139.64x

EV/FCF

ACRV

-0.63x

RLYB

-0.10x

Growth & revenue

Revenue Growth TTM

RLYB

-15.1%

Forward Revenue Growth

RLYB

499.1%

ACRV

406.9%

Profitability & performance

Gross Margin

ACRV

0.0%

RLYB

0.0%

ROE

RLYB

68.6%

ACRV

-7014.0%

FCF Yield %

RLYB

29.6%

ACRV

-78.5%

52-Week Performance

RLYB

269.6%

ACRV

1.6%

Detailed metrics comparison

ACRV

Acrivon Therapeutics Inc

RLYB

Rallybio Corp

Market Cap

ACRV$82M

RLYB$90M

Enterprise Value

ACRV$40M

RLYB$-3M

Price

ACRV$1.91

RLYB$17.02

P/E Ratio

ACRVN/A

RLYB2.17x

P/S Ratio

ACRV0.00x

RLYB139.64x

EV/Sales

ACRV0.00x

RLYB-4.09x

EV/EBITDA

ACRV0.00x

RLYB-0.10x

P/B Ratio

ACRV0.98x

RLYB0.96x

P/FCF Ratio

ACRVN/A

RLYB3.38x

EV/FCF

ACRV-0.63x

RLYB-0.10x

PEG Ratio

ACRVN/A

RLYBN/A

Forward P/E (NTM)

ACRVN/A

RLYBN/A

Forward P/S (NTM)

ACRVN/A

RLYBN/A

Revenue (TTM)

ACRV$0

RLYB$646K

Revenue Growth (YoY)

ACRVN/A

RLYB-15.1%

Forward Rev Growth

ACRV406.9%

RLYB499.1%

Gross Margin (TTM)

ACRV0.0%

RLYB0.0%

Operating Margin (TTM)

ACRV0.0%

RLYB0.0%

EBITDA Margin (TTM)

ACRV0.0%

RLYB-4284.8%

Net Margin (TTM)

ACRV0.0%

RLYB7051.2%

FCF Margin (TTM)

ACRVN/A

RLYB4135.0%

Net Income (TTM)

ACRV$-74M

RLYB$46M

FCF (TTM)

ACRV$-64M

RLYB$27M

EPS (TTM)

ACRV-$1.77

RLYB$7.86

ROE (TTM)

ACRV-7014.0%

RLYB68.6%

ROA (TTM)

ACRV-6161.0%

RLYB64.5%

ROIC (TTM)

ACRV-7014.0%

RLYB68.6%

Cash

ACRV$41M

RLYB$93M

Debt

ACRV$0

RLYB$0

Net Cash/Debt

ACRV$41M

RLYB$93M

Current Ratio (TTM)

ACRV7.99x

RLYB27.26x

Quick Ratio (TTM)

ACRV7.86x

RLYB27.01x

Debt/Equity (TTM)

ACRV0.00x

RLYB0.00x

Debt/Assets (TTM)

ACRV0.0%

RLYB0.0%

Interest Coverage (TTM)

ACRVN/A

RLYBN/A

Net Debt/EBITDA (TTM)

ACRV0.00x

RLYB0.00x

Beta

ACRV1.95

RLYB-0.75

52W Performance

ACRV1.6%

RLYB269.6%

YTD Performance

ACRV-22.4%

RLYB200.8%

% from 52W High

ACRV-46.3%

RLYB-3.2%

% from 52W Low

ACRV50.4%

RLYB363.7%

Asset Turnover (TTM)

ACRV0.00x

RLYB0.01x

FCF Yield (TTM)

ACRV-78.5%

RLYB29.6%

Earnings Yield (TTM)

ACRV-90.8%

RLYB50.5%

Dividend Yield (TTM)

ACRVN/A

RLYBN/A

Rule of 40

ACRV0.0

RLYB4,119.9

EV/GP/RG

ACRVN/A

RLYBN/A

Ticker research

View ACRV research View RLYB research

Metric	ACRV Acrivon Therapeutics Inc	RLYB Rallybio Corp
Market & Valuation
Market Cap	$82M	$90M
Enterprise Value	$40M	$-3M
Price	$1.91	$17.02
P/E Ratio	N/A	2.17x
P/S Ratio	0.00x	139.64x
EV/Sales	0.00x	-4.09x
EV/EBITDA	0.00x	-0.10x
P/B Ratio	0.98x	0.96x
P/FCF Ratio	N/A	3.38x
EV/FCF	-0.63x	-0.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$646K
Revenue Growth (YoY)	N/A	-15.1%
Forward Rev Growth	406.9%	499.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-4284.8%
Net Margin (TTM)	0.0%	7051.2%
FCF Margin (TTM)	N/A	4135.0%
Net Income (TTM)	$-74M	$46M
FCF (TTM)	$-64M	$27M
EPS (TTM)	-$1.77	$7.86
ROE (TTM)	-7014.0%	68.6%
ROA (TTM)	-6161.0%	64.5%
ROIC (TTM)	-7014.0%	68.6%
Financial Health
Cash	$41M	$93M
Debt	$0	$0
Net Cash/Debt	$41M	$93M
Current Ratio (TTM)	7.99x	27.26x
Quick Ratio (TTM)	7.86x	27.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.95	-0.75
52W Performance	1.6%	269.6%
YTD Performance	-22.4%	200.8%
% from 52W High	-46.3%	-3.2%
% from 52W Low	50.4%	363.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-78.5%	29.6%
Earnings Yield (TTM)	-90.8%	50.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	4,119.9
EV/GP/RG	N/A	N/A
Ticker research	View ACRV research	View RLYB research